FDA
-
-
-
-
-
-
-
Immunovant (IMVT) PT Raised to Street High $60 at Citi, Remains Top Pick
-
-
-
-
-
-
-
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022
-
-
-
-
-
-
-
Immunovant (IMVT) Shares Gain 6% After Reaching FDA Alignment, Analyst Sees 45% Upside
-
-
-
-
-
-
-
Immunovant (IMVT) Conference Update Highlights Early PoC in Multi Billion Market - Credit Suisse
-
-
-
-
-
-
-
Corbus Pharmaceuticals Announces Changes to its Board and Appointment of Pete Salzmann, M.D. as Independent Director
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

